Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
38.24 USD | -0.88% | +3.35% | +88.84% |
Financials (USD)
Sales 2024 * | 145M | Sales 2025 * | 261M | Capitalization | 1.44B |
---|---|---|---|---|---|
Net income 2024 * | -140M | Net income 2025 * | -51M | EV / Sales 2024 * | 8.96 x |
Net cash position 2024 * | 142M | Net cash position 2025 * | 115M | EV / Sales 2025 * | 5.1 x |
P/E ratio 2024 * |
-10.1
x | P/E ratio 2025 * |
-27.1
x | Employees | 244 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 87.91% |
Latest transcript on Tarsus Pharmaceuticals, Inc.
1 day | -0.88% | ||
1 week | +3.35% | ||
Current month | +21.67% | ||
1 month | +11.10% | ||
3 months | +24.56% | ||
6 months | +102.76% | ||
Current year | +88.84% |
Managers | Title | Age | Since |
---|---|---|---|
Bobak Azamian
CEO | Chief Executive Officer | 46 | 16-12-31 |
Jeffrey Farrow
DFI | Director of Finance/CFO | 62 | 23-04-23 |
Sesha Neervannan
COO | Chief Operating Officer | 56 | 20-07-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Bill Link
BRD | Director/Board Member | 78 | 16-12-31 |
Wendy Yarno
BRD | Director/Board Member | 69 | 20-11-18 |
Director/Board Member | 69 | 19-11-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.02% | 0 M€ | 0.00% | - | |
0.00% | 9 M€ | +11.05% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 38.24 | -0.88% | 586,985 |
24-05-16 | 38.58 | +0.21% | 357,017 |
24-05-15 | 38.5 | +1.34% | 372,374 |
24-05-14 | 37.99 | -0.99% | 575,357 |
24-05-13 | 38.37 | +3.70% | 641,961 |
Delayed Quote Nasdaq, May 17, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+88.84% | 1.46B | |
+32.09% | 694B | |
+29.39% | 593B | |
-1.34% | 371B | |
+20.34% | 331B | |
+7.39% | 290B | |
+14.25% | 239B | |
-3.03% | 209B | |
+10.02% | 209B | |
+8.49% | 169B |
- Stock Market
- Equities
- TARS Stock